期刊文献+

内质网应激激活与依托泊甙和放线菌素D耐药绒癌相关性研究 被引量:2

The relationship of the activation of endoplasmic reticulum stress and chemoresistance to Actinomycin-D and Etoposide in choriocarcinoma
原文传递
导出
摘要 目的探讨内质网应激激活与拓扑异构酶Ⅱα介导的依托泊甙(etoposide,VP16)和放线菌素D(actinomy-cin-D,Act-D)耐药绒癌的关系。方法采用间断诱导法诱导人绒癌细胞系JEG-3,分别建立绒癌ActD耐药细胞系JEG-3/ActDB1和VP16耐药细胞系JEG-3/VPC1。细胞计数法(cell counting kit-8,CCK-8)观察敏感细胞和耐药细胞的生长增殖规律和耐药指数;流式细胞仪检测细胞周期比例和染色体倍性变化;荧光定量PCR技术分别检测两种不同药物诱导的JEG-3耐药株中拓扑异构酶Ⅱα(TopoⅡα)和内质网应激(ERS)各个通路相关的基因mR-NA的表达水平。结果 (1)成功建立了绒癌耐药细胞系JEG-3/ActDB1和JEG-3/VPC1。其耐药指数分别为50.64±10.68和65.87±3.19。耐药株生长速度均较亲本细胞减慢,三者的染色体倍性差异无统计学意义。(2)在两种不同的耐药株中,TopoⅡα的表达水平均明显低于亲本细胞,而与ERS各个通路相关基因均有不同程度的激活。结论成功建立了针对ActD和VP16耐药的绒癌细胞系JEG-3/ActDB1和JEG-3/VPC1。内质网应激激活可能参与绒癌耐药的发生。 Objective To investigate the relationship of endoplasmic reticulum stress (ERS) and topoisomerase IIα (TopolIct) expression in the mechanism of actinomycin-D (ActD) and etoposide (VP16)-resistant human choriocarcinoma. Methods The ActD-and VP-resistant sub-line were established by intermitted exposure to grads increased chemotherapy reagent respectively. Population doubling time was calculated and compared based on the growth curve of these cell lines, cell cycles and chromosomal ploidy were assayed with flowcytometry methods. The resistant index (RI) was measured by Cell Counting Kit-8 ( CCK-8 ) assay, qRT-PCR was used to detect the mRNA expression level of TopoIIα and the genes involved in the pathway of ERS. Results ( 1 ) The RI of JEG-3/ActDBI and JEG-3/VPC1 were 50. 64 ± 10. 68 and 65.87 ± 3. 19 respectively. Compared with the JEG-3 cell line, the chemo-resistant sub-line had gross changes in morphological, cell growth and cell cycles. (2) The transcript expression level of TopoIIα were significant down-regulated in chemo-resistant sub-lines, while the genes involved in ER-related pathway were changed to certain extension by comparing with parent cell line and chemo-resistance sub-lines. Conclusion We successfully established the ActD-and VP16-resistant sub-line of JEG-3 respectively. The activation of ERS related pathway may involved in chemo-resistance of choriocarcinoma.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2011年第11期835-838,共4页 Chinese Journal of Practical Gynecology and Obstetrics
基金 国家教委博士点专项基金(基金编号:200800230001)
关键词 绒癌 JEG-3细胞系 耐药 放线菌素D 依托泊甙 拓扑异构酶Ⅱα 内质网应激 choriocarcinoma JEG-3 cell line chemoresistant actinomycin-D etoposide topoisomerase IIα endoplasmic reticulum stress
  • 相关文献

参考文献12

  • 1Noal S, Joly F, Leblanc E. Management of gestational trophoblastic disease[J]. Gynecol Obstet Fertil,2010,38:193-198.
  • 2Zhao Y, Zhang W, Duan W. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northem China[J]. J Reprod Med, 2009,54:88-94.
  • 3ChampouxJJ. DNA topoisomerases: structure, function, and mechanism[ J]. Annu Rev Biochem, 2001,70:369-413.
  • 4Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo [ J ]. Proc Natl Acad Sci USA, 2008,105:9053-9058.
  • 5Gray MD, Mann M, Nitiss JL, et al. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomersse IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs[J]. Mol Pharmacol, 2005,68:1699- 1707.
  • 6韩冰,向阳,沙桂华,张浩,刘欣.绒毛膜癌氟尿苷耐药细胞系的建立及其胸苷合成酶的表达[J].中华妇产科杂志,2009,44(11):851-855. 被引量:6
  • 7Derveaux S, Vandesompele J, Hellemans J. How to do successful gene expression analysis using real-time PCR[ J]. Methods, 2010,50:227-230.
  • 8Coss A, Tosetto M, Fox EJ, et al. Increased topoisomerase llalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis[ J]. Cancer Lett,2009,276:228-238.
  • 9Gosky D, Chatterjee S. Down-regulation of topoisomerase 11 alpha is caused by up-regulation of GRP78 [ J ]. Biochem Biophys Res Commun, 2003,300:327-332.
  • 10Yun J, Tomida A, Andoh T, et al. Interaction between glucose-regulated destruction domain of DNA topoisomerase Ilalpha and MPN domain of Jabl/CSN5 [ J ]. J Biol C hem,2004,279: 3 1296-31303.

二级参考文献15

  • 1Li L, Luan Y, Wang G, et al. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med, 2004, 14:257-264.
  • 2Matsui H, Iitsuka Y, Suzuka K, et al. Salvage chemotherapy for high-risk gestational trophoblastic tumor. J Reprod Med, 2004, 49:438-442.
  • 3Cunningham FG, Gant NF, Kenneth JL. Williams Obstetrics. 21 st. New York : McGraw-hill ,2002:569.
  • 4Jakoby WB. Methods in enzmology, Vol I. Cell culture. New York: Acad Press, 1979 : 150.
  • 5Lala PK, Lee BP, Xu G, et al. Human placental trophoblast as an in vitro model for tumor progression. Can J Physiol Pharmacol, 2002, 80 : 142-149.
  • 6van Laar JA, Rustum YM, Ackland SP, et al. Comparison of 5- fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer, 1998, 34:296-306.
  • 7Maring JG, Groen HJ, Wachters FM, et al. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J, 2005, 5 :226-243.
  • 8Snow K, Judd W. Characterisation of adriamycin- and amsacrine- resistant human leukaemic T cell lines. Br J Cancer, 1991, 63: 17-28.
  • 9van Triest B, Pinedo HM, van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5- fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res, 1999, 5:643-654.
  • 10Aschele C, Debernardis D, Bandelloni R, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5- lluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol, 2002, 13 : 1882-1892.

共引文献5

同被引文献11

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部